Form 4: Acrivon Therapeutics Executive Katharine Peterson Reports Stock Option Grant

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the acquisition of stock options.

Summary

• Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc. [ACRV], filed a Form 4 on March 4, 2025, reporting a transaction on March 1, 2025.
• Peterson acquired stock options (right to buy) for 31,900 shares of common stock at an exercise price of $5.31.
• These options vest over time, with 25% vesting on March 1, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule is typical, designed to incentivize long-term commitment and performance.
• Comparable companies such as Arvinas, Inc. and Relay Therapeutics, Inc. also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates